RARE News and Press, Ultragenyx Pharmaceutical Inc. From 07/06/23

Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical In...

2023-06-27 07:00:00 ET Summary With the cost of living has increased dramatically, we're all seeking ways to increase our income. Getting double-digit yields with high-yield stocks is a risky proposition. However, exploiting human nature, we can safely generate higher yields w...

BEDFORD, Mass., June 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today officially opened its gene therapy manufacturing facility in Bedford, Massa...

NOVATO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the c...

2023-06-06 08:23:18 ET Shares of Ultragenyx Pharmaceutical ( NASDAQ: RARE ) and Mereo BioPharma ( MREO ) gained in the pre-market Tuesday after the biotechs announced mid-stage data for setrusumab, a monoclonal antibody targeted at the bone disorder osteogenesis imperfecta (OI)....

2023-06-05 17:18:34 ET Gainers: GitLab  ( GTLB ) +19% . HealthEquity ( HQY ) +6% . Kezar Life Sciences ( KZR ) +5% . Ultragenyx Pharmaceutical  ( RARE ) +4% . Vaxxinity ( VAXX ) +3% . Losers: Chijet Motor Compan...

Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to screen patients Conference call to discuss data planned for 5 p.m. Eastern Time ...

2023-05-29 07:15:02 ET Summary Ultragenyx's pipeline boasts a diverse array of gene therapy candidates, including UX111, DTX401, DTX301, and UX701, offering transformative potential in the treatment of multiple rare genetic diseases. The FDA recently approved amendments to the Pha...

2023-05-29 05:19:13 ET Summary Mereo BioPharma's focus on rare diseases draws interest, but concerns about setrusumab's efficacy persist. Increased R&D and administrative expenses led to a substantial net loss for Mereo in 2022. The company has reached key milestones, incl...

2023-05-22 08:53:35 ET Summary Ultragenyx has a healthy rare disease product and pipeline. There are some issues with its next emerging catalyst. Despite those doubts, the company, as a whole, is very healthy. In November, I said that although I like Ultragenyx ( R...